ArticleFrontiers in neurology2022
Recurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Cohort Study in Central China.
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- A qualitative exploration of patient experiences living with autoimmune encephalitis.Scientific reports · 2026Article
- Blood-brain barrier integrity disruption linked to brain lesions and relapse prediction in Southern Chinese anti-NMDAR encephalitis patients.Frontiers in cellular neuroscience · 2026Article
- Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.Journal of neurology · 2025Article
- A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial.Neurology open access · 2025Article
- Efficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis.Heliyon · 2025Article
- Assessment of clinical prognosis in autoimmune encephalitis: Girona score.Frontiers in psychiatry · 2025Article
- Late relapse of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: a case report.Journal of medical case reports · 2024Article
- Development of a short-term prognostic model for anti-N-methyl-D-aspartate receptor encephalitis in Chinese patients.BMC neurology · 2024Article
- Identifying Key Prognostic Indicators for Relapse and Chronic Epilepsy in Autoimmune Encephalitis: Insights from a Multicenter Retrospective Study.Journal of inflammation research · 2024Article
- Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate factors that could impact or predict the probability of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis recurrence in central China. Methods: From November 2014 to October 2020, observational data of anti-NMDAR encephalitis inpatients in our institution were collected and analyzed prospectively. The demographics, clinical characteristics, tumor status, lesion locations on MRI and immunotherapies, etc. had entered into a Cox regression model for the identification of the factors associated with relapse-free survival. Results: We enrolled 113 patients in a row (median age: 28 years, range: 1-61 years). The gender distribution was not statistically significant ( Conclusions: Anti-NMDAR encephalitis can recur in around one out of every six cases, and symptoms are generally milder than when it first appears. Recurrence is not related to the severity in the acute phase or the prognosis at follow-up. Patients with ≥3 abnormal sites on MRI or lesions located in the brainstem at onset must be alert to the possibility of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.